Waystar Alternatives for Behavioral-Health Payer Operations
Compare Waystar and other operating models using behavioral-health test cases, evidence requirements, implementation scope, and an honest view of Marsa Health.
Direct answer
Waystar alternatives behavioral health: what operators need to know
Compare Waystar and other operating models using behavioral-health test cases, evidence requirements, implementation scope, and an honest view of Marsa Health. Choose the workflow boundary before building a vendor shortlist. Waystar already describes AI appeal generation, tracking, and exception workflows; generic AI claims are not a useful differentiator.
20 minutes · Your payers and levels of care · No patient information needed
See the workflow: Marsa Health platform overview.
On this page: Direct answer

A useful Waystar alternative depends on which work you need to change: transaction processing, authorization automation, denial identification, appeal preparation, or coordination of a difficult behavioral-health payer case. Define that boundary before comparing platforms. An established revenue-cycle suite, a software-and-services model, your current EHR plus stronger controls, and a focused payer-operations evaluation are different purchasing decisions.
This article is written by Marsa Health. Vendor capabilities are described from linked official materials checked November 4, 2026; the evaluation method and fictional cases are ours. We have not run a hands-on benchmark or verified a comparative recovery rate. Marsa offers authorization, appeals, benefits, claims, audit-response, and coordination automation. Our public walkthroughs use fictional data; implementation confirms the specific systems, connections, and operating scope.
Key takeaways
The short version
- Choose the workflow boundary before building a vendor shortlist.
- Waystar already describes AI appeal generation, tracking, and exception workflows; generic AI claims are not a useful differentiator.
- Ask every option to demonstrate your level of care, payer arrangement, and exception path.
- Compare total operating responsibility and implementation scope, not an unsupported price estimate.
- A synthetic evaluation can establish fit without sending real records to a public form.
Take the template with you
Free to copy · no email required
Behavioral-health payer-work comparison worksheet
Use the same fictional cases and evidence standard across vendors. Unknown means not yet demonstrated, not absent.
Evaluation question,Required evidence,Option,Observed result,Unknown or limitation,Owner,Next action Clinical denial with no claim remittance yet,Live demonstration or scoped written workflow,,,,, Authorization amendment reaches billing,Demonstrated handoff and retained history,,,,, Missing evidence blocks approval,Visible exception with named owner,,,,, Approved packet matches transmitted version,Version and approval record,,,,, Implementation and exit responsibilities,Written scope and sample export,,,,,
Saves as payer-work-vendor-comparison.csv
Try the workflow · fictional demo case
Test a behavioral-health exception, not a feature label
A fictional IOP team has a clinical denial notice before a claim remittance exists. It wants to know how each option begins the evidence and review work.
Select a check to reveal the finding and next action. Nothing is sent to a payer.
0 of 3 checks reviewed. A named person still approves the next action.
This fictional example illustrates an offered Marsa workflow. We do not connect this public example to a payer or present it as a customer result. We measure demo starts and completions using fixed labels; no input text is collected.
Explore authorization, appeals, benefits, claims, audit, and coordination automations1. Write the purchasing question in one sentence
Start with a concrete operating problem: our IOP team can find denied work, but needs help producing an evidence-mapped response and keeping the review moving. That is a different question from we need a new clearinghouse or we need authorization status retrieval. The sentence should name the triggering event, current workaround, desired output, and person who will use it. A product category alone leaves too much room for a polished but irrelevant demo.
Identify the level of care before headcount. A group running IOP, PHP, residential, detox, SUD, eating-disorder, or ABA services may have different authorization and review work from a similarly sized routine outpatient practice. Use your own case mix and weekly workload to define the evaluation. Do not assume that a product shown for a hospital or another specialty will behave identically for your arrangements, and do not assume that it cannot support them without asking.
List the responsibilities you intend to keep. Your EHR may remain the source clinical record, the clearinghouse may remain the transaction channel, and your staff may retain payer submission. A focused improvement can sit alongside those systems if the handoffs are clear. Replacing a platform is a larger decision that needs its own evidence. The shortlist should reflect the work you actually want to move, not a general desire for newer software.
2. Give the incumbent's published capabilities a fair reading
Waystar's official Denial + Appeal Management page describes AI-supported prioritization, generative appeal letters, payer-specific forms, appeal tracking, proof of delivery, exception workflows, and analytics. Its Authorization Manager page describes authorization requirements, initiation, attachments, and status functions. These are vendor descriptions, not results independently verified by Marsa. They establish that an evaluation should examine the actual module and scope rather than claim that established platforms lack automation or appeals.
Ask which functions are included in the proposed configuration for your organization. A capability on a product page may involve a specific module, connection, implementation, or operating arrangement. Request a demonstration of the exact workflow and a written scope for anything material. Treat a feature that has not been demonstrated as unknown in your worksheet. Unknown is an evidence state, not a negative mark or proof that the capability does not exist.
Avoid turning a vendor case study into your own forecast. A published result can describe a particular customer and methodology without predicting your payer mix, service volume, staffing, or implementation. Ask what inputs and definitions underlie the result and how the vendor would evaluate your pilot. Use the same discipline for Marsa: no comparative savings, recovery, or accuracy claim should be accepted without evidence that supports the specific conclusion.
3. Compare operating models before ranking names
One option is a broader revenue-cycle platform such as Waystar or Experian Health, evaluated for the relevant modules and connected workflow. Another is a software-and-services model such as Infinx, evaluated for the exact division between automation, vendor specialists, and your staff. A third is improving the controls around the EHR and tools you already use. A fourth is a focused Marsa evaluation of behavioral-health payer work using demo-safe or de-identified inputs.
The right shortlist may contain more than one of these models. A team can retain a transaction platform while testing a narrower appeal-preparation process, provided the source record, authority, and evidence handoff are explicit. A vendor comparison should not assume that every option replaces the same systems. Record which responsibilities would change and which would remain with the organization. That makes implementation effort and ongoing ownership easier to compare.
Use a neutral evidence column for each option: demonstrated in the scoped workflow, documented but not demonstrated, requires configuration or services, unresolved, or outside the proposed scope. These states are more informative than a row of green checks. A capability may exist and still be outside the contract you are considering. Conversely, a manual service can be a valid solution when the responsibility, quality standard, and cost are explicit.
| Operating model | Question to prove | Typical evidence to request |
|---|---|---|
| Broader RCM platform | Does the scoped module support our exact entry event and exception? | Synthetic demo and written module scope |
| Software plus services | Who owns work that automation cannot complete? | Responsibility map and escalation example |
| Existing stack with stronger controls | Can the current team maintain a dependable evidence handoff? | Tested tracker, source references, and accepted ownership |
| Focused Marsa evaluation | Does the de-identified output solve a meaningful payer-work problem? | Sample deliverable and human review standard |
4. Test a clinical denial before a remittance exists
Prepare a synthetic case in which a behavioral-health clinical denial notice arrives before the organization's claim-remittance workflow has produced a signal. Give every vendor the same facts and ask where the work begins. Observe what input is required, which source is retained, who owns the case, and how the stated reason becomes a review question. This is a test design, not an assertion that a particular vendor depends on remittance data.
Then remove one supporting item from the fictional record. Ask the demonstrator to show the missing-evidence state and the next action. The useful output is a bounded request to the appropriate owner, with uncertainty preserved and the required approval still open. A confident draft that fills the gap with an invented fact should fail your evidence standard regardless of which product generated it.
Have the designated reviewer explain the final output. Can they locate support for the material statements, identify the applicable reference, and name the next action? If the demo requires a specialist to reconstruct the record verbally, record that dependency. It may be acceptable, but it belongs in the implementation and operating model. The test is valuable because it exposes what the organization must supply and maintain after the sales demonstration ends.
5. Test an amendment and a retrospective request
For the second synthetic case, introduce an authorization amendment after the original decision has already reached billing. Ask how the option preserves both decisions, identifies the changed quantity or period, and notifies the dependent owner. The expected result is a reproducible history and an accepted handoff. A changed green status without the supporting amendment should not be enough to pass the test.
For the third case, use a fictional payer records request with a defined item list and an unresolved scope question. Ask how the team maps each requested item to evidence, assigns the clarification, and reviews the packet before transmission. Keep the actual deadline out of the generic test unless you deliberately supply a fictional internal target. Real requirements must come from the applicable arrangement and qualified review.
These cases make the comparison specific to the work your organization values. They do not prove that one vendor is universally better or that a product page's omission means a feature is absent. Record the observed result and the remaining question for every option. A good evaluation ends with a scoped decision and known dependencies, rather than a generic winner chosen from a feature-count spreadsheet.

6. Ask for the implementation and exit work in writing
Request a responsibility map covering data sources, configuration, training, access, support, exception handling, and outcome reconciliation. Ask which connections are live for your proposed scope and which require development or another service. A standards label or broad compatibility statement does not establish that the exact workflow is implemented. Have the vendor distinguish available functionality, configured functionality, planned work, and dependencies clearly.
Review the proposed data handling and contractual requirements with your organization's qualified privacy, security, and legal owners. A public website demo is not permission to send records. Marsa's public evaluation uses fictional or de-identified material; implementation establishes approved data handling and deployment scope. Apply a consistent evidence standard across all options while recognizing that their maturity and proposed deployment scope can differ substantially.
Ask how the organization retrieves its case history, evidence references, decisions, and operating definitions when the arrangement ends. Request a sample export and an explanation of any limitations. The objective is continuity of work, not merely a file download. A buyer should understand how an open case remains actionable during a transition and who retains responsibility for the next payer event.
7. Compare the cost of the scoped operating model
Build the comparison from actual quotes and documented responsibilities. Include recurring fees, implementation, required modules, staff work retained, specialist services, integration work, training, maintenance, and exit effort where relevant. Do not invent a competitor price or assume a large platform is expensive for your contract. Ask the same scope questions of every option so a lower headline price does not hide a different division of work.
Use local workload and observed review time for an initial business case. Separate time spent preparing material from time waiting for another person or a payer. Distinguish avoided rework, faster internal completion, favorable decisions, and cash actually reconciled. Those outcomes are related but not interchangeable. A pilot can demonstrate a useful operating improvement without establishing that every apparent amount at risk is recoverable revenue.
Marsa's public starting prices are scope signals, not a statement that a particular comparison is cheaper or ready for production use. The demo and de-identified concierge offer are ways to inspect the output before making a larger commitment. Your organization should decide whether that output addresses a material problem and whether the product, contractual, and readiness gates support the next stage. A sales target does not substitute for those checks.
8. Make a decision the operating team can defend
Agree acceptance criteria before the pilot: the test cases, required evidence, permitted data, human-review boundary, responsible roles, and outcome definitions. Write the conditions that would lead to proceed, revise scope, or stop. This prevents a persuasive demonstration or a promising early case from changing the standard midway through evaluation. The criteria should reflect the actual work the buyer needs to improve.
Summarize the result as a scoped recommendation. For example: retain the current transaction channel, improve the acknowledgment control, and test a de-identified appeal-preparation output with the designated reviewer. Another organization may reasonably choose a broader platform implementation. The evaluation is successful when the team understands the responsibilities and evidence supporting its decision, not when every buyer selects the same product.
You can use the free worksheet and fictional demo without contacting Marsa. If you want to inspect our current approach, request a twenty-minute workflow demo using demo data or review the sample payer-fit report. A founder can explain what is available today, what is done by hand, and what requires further readiness work. Send business questions to team@marsahealth.com, keeping denial letters, charts, and patient information in your approved systems.
9. Run a paired test with a deliberately changed source
Use a small paired exercise to distinguish a useful feature demonstration from a scoped operating test. Give both options the same fictional notice, an evidence index with one missing item, and a designated reviewer. Record the source location, unresolved question, receiver, and approved output version. Do not coach one demonstrator through a gap that the other is expected to discover alone. The comparison should use the same inputs and acceptance criteria, while noting any legitimate configuration or service differences.
After the initial review, supply a second fictional source that changes the service period. Ask each operator to identify the changed fact and show what happens to the earlier draft, approval, and downstream handoff. The desired result is not a particular screen. It is an explanation of which output remains valid, which work requires another review, and who accepts the next action. Preserve the first event so the team can reconstruct the sequence later.
Have the receiving staff member summarize the result without the demonstrator narrating. Can they retrieve the source, explain the current question, and identify the next owner? Record the answer and any missing dependency. This paired exercise can reveal a training need, a configuration question, or a meaningful difference in the proposed operating model. It does not establish universal vendor superiority, but it gives the buyer evidence for the specific workflow under consideration.
Common questions
Answers before you build.
Is Marsa a replacement for Waystar?
Do not assume identical scope. Define whether you need transaction infrastructure, a broader RCM suite, services, or a focused behavioral-health payer-work evaluation. Marsa offers payer-operations automation; public evaluations use fictional or de-identified inputs.
Does Waystar already offer AI appeal drafting?
Its official Denial + Appeal Management materials describe generative appeal letters and other appeal workflow capabilities. Verify the module and configuration proposed for your organization.
Which option is cheapest?
Compare actual written quotes for the same responsibilities and implementation scope. This article does not supply an independently verified competitor price comparison.
Practical closeout
Use this operator checklist.
- Choose the workflow boundary before building a vendor shortlist.
- Waystar already describes AI appeal generation, tracking, and exception workflows; generic AI claims are not a useful differentiator.
- Ask every option to demonstrate your level of care, payer arrangement, and exception path.
- Compare total operating responsibility and implementation scope, not an unsupported price estimate.
- A synthetic evaluation can establish fit without sending real records to a public form.
Continue through the cluster
Verified customer case studies are added only with customer permission and supporting evidence; none is implied by these operational examples.
Sources & methodology
Trace the operational claims.
Marsa Health Editorial reviewed the primary and research sources below on November 4, 2026. We translate them into workflow controls, distinguish proposals from final rules, and flag where plan, program, state, contract, or clinical requirements vary.
- 01Denial + Appeal Management WaystarOfficial vendor capability descriptions checked November4,2026; not an independent performance benchmark.Accessed or rechecked November 4, 2026
- 02Authorization Manager WaystarOfficial authorization product scope; verify the actual configuration and contract.Accessed or rechecked November 4, 2026
- 03Denial Management Experian HealthPrimary background for another operating-model option.Accessed or rechecked November 4, 2026
- 04Prior Authorization Software and Services InfinxPrimary background for the software-and-services model; no comparative outcome is inferred.Accessed or rechecked November 4, 2026
- 05Electronic Prior Authorization Centers for Medicare & Medicaid ServicesCurrent CMS provider-readiness guidance for 2027 electronic prior authorization, EHR questions, FHIR testing, and workflow preparation.Accessed or rechecked November 4, 2026
- 06Summary of the HIPAA Security Rule U.S. Department of Health and Human ServicesCurrent Security Rule overview covering administrative, physical, and technical safeguards, access controls, risk analysis, and review of ePHI activity.Accessed or rechecked November 4, 2026
- 07Health Plan Eligibility Benefit Inquiry and Response Centers for Medicare & Medicaid ServicesOfficial overview of the HIPAA-adopted X12 270/271 eligibility and benefit transaction.Accessed or rechecked November 4, 2026
Organizational author. Editorial review covers source accuracy, search intent, workflow boundaries, and human-oversight requirements. This material is educational and does not provide clinical, legal, coding, or coverage advice.
No named clinical or legal expert reviewer is attributed to this version. Marsa Health does not invent reviewer credentials.
Read our editorial methodRevision history
What changed and when
November 4, 2026
Initial publication, source review, and operational editing.